A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure
- 1 January 1992
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 123 (1) , 95-103
- https://doi.org/10.1016/0002-8703(92)90752-h
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.Circulation, 1990
- Enoximone in chronic heart failure.Circulation, 1990
- A Comparison of Oral Milrinone, Digoxin, and Their Combination in the Treatment of Patients with Chronic Heart FailureNew England Journal of Medicine, 1989
- Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins.Circulation Research, 1989
- Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic propertiesEuropean Journal of Pharmacology, 1986
- Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.Circulation, 1985
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.Circulation, 1979
- Hemodynamic Assessment of AmrinoneNew England Journal of Medicine, 1978